Showing 951-960 of 1635 results for "".
- Harrow and iOR Partners Expand National Product Supply Agreementhttps://modernod.com/news/harrow-and-ior-partners-expand-national-product-supply-agreement/2481267/Harrow and iOR Partners jointly announced the expansion of their national product supply agreement to provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.</
- Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseaseshttps://modernod.com/news/opus-genetics-sponsors-uni-rare-natural-history-study-for-people-with-inherited-retinal-diseases/2481239/Opus Genetics announced the company will co-sponsor the Uni-Rare Study, a new natural history study for approximately 1,500 people with mutations in one of more than 300 rare genes associated with inherited retinal diseases (IRDs). The two-part Uni-Rare Study is being launched to charac
- BioTissue Completes Name Changehttps://modernod.com/news/biotissue-completes-name-change/2481211/BioTissue Holdings announced the completion of its name change from TissueTech. The change is part of a corporate-wide branding initiative launched earlier this year to better represent the company’s entire portfolio and pipeline of products. Pursuant to the name change, the former Tis
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care/2481193/Nanodropper launched its "2022 Give the Gift of Vision" program, an effort to donate 1,000 Nanodropper adaptors to at-need patients in the United States and its global nonprofit partners—designed to deliver better access to vision-saving care in low resource settings in
- Oculis SA and European Biotech Acquisition Corp Announce Agreement to Create Nasdaq-Listed Biopharmaceutical Companyhttps://modernod.com/news/oculis-sa-and-european-biotech-acquisition-corp-announce-agreement-to-create-nasdaq-listed-biopharmaceutical-company/2481177/Oculis SA and European Biotech Acquisition Corp (EBAC) announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be named “Oculis Holding SA” and will work to accelerate the development of Oculis&rsqu
- Nanoscope Announces Completion of Enrollment in STARLIGHT Phase 2 Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Diseasehttps://modernod.com/news/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease/2481089/Nanoscope Therapeutics announced full enrollment of its phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for Stargardt disease. Six-month data from the phase 2 STARLIGHT trial are exp
- TearLab Announces Corporate Name Change to Trukera Medical; Targets Corneal Healthhttps://modernod.com/news/tearlab-announces-corporate-name-change-to-trukera-medical-targets-corneal-health/2481067/TearLab announced that it will be expanding its position in corneal health under the new name Trukera Medical. The rebranding reflects the company’s vision and future growth strategy targeting a broader set of unmet needs across corneal health. “We continue to rema
- Alcon’s Sue-Jean Lin Named 2022 US National CIO of the Yearhttps://modernod.com/news/alcons-sue-jean-lin-named-2022-us-national-cio-of-the-year/2481019/Alcon announced that Sue-Jean Lin, Senior Vice President and Chief Information and Transformation Officer, was awarded the 2022 U.S. National CIO of the Year ORBIE Award in the "Global" category for multinational companies over $5 billion in annual revenue. This follows her recognition
- Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Diseasehttps://modernod.com/news/nanoscope-therapeutics-announces-first-patient-dosed-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease/2480985/Nanoscope Therapeutics announced that the first patient has been dosed in a phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy for Stargardt disease. “This trial represents the second indication for our vision restoring
- Prevent Blindness Holds 11th Annual Focus on Eye Health National Summit as Two-Day Virtual Eventhttps://modernod.com/news/prevent-blindness-holds-11th-annual-focus-on-eye-health-national-summit-as-two-day-virtual-event/2480966/Preventg Blindness held the 11th annual Prevent Blindness Focus on Eye Health National Summit as a virtual event on July 13-14, 2022. This year’s Summit engaged more than 840 registered attendees, and included a variety of presentations related to the theme "Eye-conic Ap